Loading...
Market
Number of EU countries adopting seladelpar in health systems by December 31, 2025
2
Resolution / Starting Odds
More than 20 countries • 25%
15-20 countries • 25%
10-14 countries • 25%
Less than 10 countries • 25%
Health policy updates from EU member states
Story
Gilead's Seladelpar Gets Positive CHMP Opinion for PBC, Shows 62% Response Rate
Dec 13, 2024, 11:39 AM
Gilead Sciences, Inc. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug seladelpar, intended for the treatment of primary biliary cholangitis (PBC) in adults. The recommendation is based on the results from the pivotal placebo-controlled Phase 3 RESPONSE study, which demonstrated that seladelpar achieved a composite biochemical response in 62% of participants at month 12, compared to 20% with placebo. Additionally, 25% of participants on seladelpar normalized their alkaline phosphatase (ALP) levels, a key marker of disease progression in PBC. The drug also significantly reduced pruritus, a common and debilitating symptom of PBC. If approved by the European Commission, seladelpar would provide an important new treatment option for PBC patients in the EU, where the disease affects approximately 15 per 100,000 people, primarily women.
View original story
Similar markets
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16+ countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%